Adaptive Biotechnologies Corporation (ADPT:NASDAQ) closed at $29.04 on November 13, 2026, down 1.49% on the day. The stock trades 9.8% below its 52-week high of $32.21 and 142.0% above its 52-week low of $12.00. Over the past year, it gained 106.0%. Adaptive Biotechnologies Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, ADPT closed higher on 128 days (51%). Its best day was January 12, 2026 (+15.86%) and its worst was December 5, 2025 (-15.52%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 2 times.
Adaptive Biotechnologies Corp is a a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Find more stocks like ADPT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.